Cymabay Therapeutics Incorporated (NASDAQ:CBAY)’s Stock Is Buy After Less Market Selling

January 14, 2018 - By Peter Erickson

 Cymabay Therapeutics Incorporated (NASDAQ:CBAY)'s Stock Is Buy After Less Market Selling

The stock of Cymabay Therapeutics Incorporated (NASDAQ:CBAY) registered a decrease of 10.94% in short interest. CBAY’s total short interest was 2.22M shares in January as published by FINRA. Its down 10.94% from 2.49 million shares, reported previously. With 493,100 shares average volume, it will take short sellers 5 days to cover their CBAY’s short positions. The short interest to Cymabay Therapeutics Incorporated’s float is 8.89%.

The stock increased 0.61% or $0.06 during the last trading session, reaching $9.97. About 314,250 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since January 14, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $437.33 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 17 analyst reports since July 21, 2015 according to SRatingsIntel. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Monday, September 11 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, October 25. On Tuesday, November 28 the stock rating was maintained by Leerink Swann with “Buy”. H.C. Wainwright initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, September 8. H.C. Wainwright has “Buy” rating and $12 target. The firm has “Buy” rating by Piper Jaffray given on Monday, July 17. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Oppenheimer on Wednesday, January 10. The company was initiated on Tuesday, July 21 by Piper Jaffray. Piper Jaffray maintained the shares of CBAY in report on Tuesday, July 25 with “Buy” rating. H.C. Wainwright maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, January 4. H.C. Wainwright has “Neutral” rating and $2.50 target. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, September 19.

More recent Cymabay Therapeutics, Inc. (NASDAQ:CBAY) news were published by: Streetinsider.com which released: “CymaBay Therapeutics (CBAY) Commences Enrollment in Long-Term Extension Study …” on January 08, 2018. Also Globenewswire.com published the news titled: “CymaBay Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference” on January 02, 2018. Nasdaq.com‘s news article titled: “CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate …” with publication date: January 08, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.